Premium
Circulating human megakaryocytes in cardiac diseases
Author(s) -
PAMPUS E. C. M.,
HUIJGENS P. C.,
ZEVENBERGEN A.,
VERHEUGT F. W. A.,
LANGENHUIJSEN M. M. A. C.
Publication year - 1994
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/j.1365-2362.1994.tb01095.x
Subject(s) - thrombopoiesis , megakaryocyte , myocardial infarction , platelet , bone marrow , medicine , infarction , immunology , cardiology , pathology , haematopoiesis , stem cell , biology , genetics
Both bone marrow and circulating megakaryocytes may produce platelets. Changes in number and properties of the circulating megakaryocytes in cardiac diseases may provide information about thrombopoiesis in these disease states. Circulating megakaryocytes were obtained by retrograde aspiration through wedged pulmonary artery catheters from patients without cardiac abnormalities, patients with cardiac diseases and patients with disorders known to affect the megakaryocyte‐platelet axis or marrowblood barrier. Their number, ploidy distribution and expression of the β 1 ‐integrin adhesion antigens were estimated. We found evidence for an increased number of circulating megakaryocytes during acute myocardial infarction and in patients with triple vessel disease. A significantly higher proportion of circulating megakaryocytes obtained within 60 h after acute myocardial infarction, expressed CDw49b (α‐chain of VLA2), CDw49e (α‐chain of VLA5), and CDw49f (α‐chain of VLA6) compared to megakaryocytes of patients without cardiac diseases. In myocardial infarction the increase in number of circulating megakaryocytes together with the higher proportion that expressed the β 1 ‐integrin adhesion antigens favour the hypothesis that these megakaryocytes are acutely released from the bone marrow. This could reflect either a selective response to an increased demand for circulating platelets or be the result of an aselective mechanism resulting from damage to the marrow‐blood barrier following the acute infarction or thrombolytic therapy administered.